Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Phase of Trial: Phase I/II
Latest Information Update: 24 Dec 2017
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Sep 2017 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
- 06 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology